Komori
Share Issuance and Disposal4575CanBas Co.,Ltd.Pharmaceuticals

Notice Regarding Completion of Payment for the Issuance through Third-Party Allotment of the 22nd Series of Stock Acquisition Rights (with an Exercise Price Adjustment Clause) and the 23rd and 24th Series of Stock Acquisition Rights (with an Exercise Price Adjustment Election Right)

Payment by the allottees of the total issuance price of ¥15.14 million for the 22nd, 23rd and 24th series of stock acquisition rights has been completed. The issuance terms for the stock acquisition rights were disclosed on 14 October 2026, and this disclosure reports the completion of payment.

Worth reading
62In focus
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
15140000
Yen
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of the 22nd Series Stock Acquisition Rights with Provisions for Revision of the Exercise Price and the 23rd and 24th Series Stock Acquisition Rights with Options for Revision of the Exercise Price by third-party allotment

Who receives how much

Total potential shares: 4,800,000 shares (2,000,000 for the 22nd series, 1,300,000 for the 23rd series and 1,500,000 for the 24th series)

株式会社SBI証券 (48,000 units)

The lower thin line represents the existing number of shares to which these shares will be added.

¥482 per unit of the 22nd series of stock acquisition rights, ¥280 per unit of the 23rd series, and ¥124 per unit of the 24th series
Total issue value

¥15,140,000

Amount of funds to be raised
¥4,175,640,000 (the total amount payable for these stock acquisition rights, the total amount payable upon exercise if all rights are exercised at the exercise price, and an estimate reflecting issuance-related expenses)
Terms of the stock acquisition rights
Exercise price
¥778 for the 22nd series, ¥855 for the 23rd series, and ¥1,010 for the 24th series. The exercise price for the 22nd series will be adjusted based on 92% of the closing price on the immediately preceding trading day, with a floor of ¥389. The exercise prices for the 23rd and 24th series will be adjusted if the Company’s Board of Directors passes a resolution electing to adjust them, with a floor of ¥389 for each.
Exercise period
2 November 2026 to 2 November 2028
Number of Stock Acquisition Rights
Total issuance: 48,000 units (20,000 for the 22nd series, 13,000 for the 23rd series and 15,000 for the 24th series). The number of unexercised units outstanding is Not disclosed.
Payment date
30 October 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of the 22nd Series Stock Acquisition Rights with Provisions for Revision of the Exercise Price and the 23rd and 24th Series Stock Acquisition Rights with Options for Revision of the Exercise Price by third-party allotment
Number of shares to be issued or disposed ofTotal potential shares: 4,800,000 shares (2,000,000 for the 22nd series, 1,300,000 for the 23rd series and 1,500,000 for the 24th series)
Issue price and disposal price¥482 per unit of the 22nd series of stock acquisition rights, ¥280 per unit of the 23rd series, and ¥124 per unit of the 24th series
Total issue value¥15,140,000
Amount of funds to be raised¥4,175,640,000 (the total amount payable for these stock acquisition rights, the total amount payable upon exercise if all rights are exercised at the exercise price, and an estimate reflecting issuance-related expenses)
Payment date30 October 2026
Intended allottee株式会社SBI証券 (48,000 units)
Exercise price¥778 for the 22nd series, ¥855 for the 23rd series, and ¥1,010 for the 24th series. The exercise price for the 22nd series will be adjusted based on 92% of the closing price on the immediately preceding trading day, with a floor of ¥389. The exercise prices for the 23rd and 24th series will be adjusted if the Company’s Board of Directors passes a resolution electing to adjust them, with a floor of ¥389 for each.
Exercise period2 November 2026 to 2 November 2028
Number of Stock Acquisition RightsTotal issuance: 48,000 units (20,000 for the 22nd series, 13,000 for the 23rd series and 15,000 for the 24th series). The number of unexercised units outstanding is Not disclosed.
Items this document does not state (18)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because payment of the total issuance price of these stock acquisition rights has been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Payment for the Issuance through Third-Party Allotment of the 22nd Series of Stock Acquisition Rights (with an Exercise Price Adjustment Clause) and the 23rd and 24th Series of Stock Acquisition Rights (with an Exercise Price Adjustment Election Right) | CanBas Co.,Ltd. (4575) timely disclosure | Komori